Oncology

Eunice Wang, MD, highlights breakthroughs in menin inhibitors for acute leukemias, showcasing promising combination therapies and addressing treatment challenges at ASH 2025.

Five key oncology FDA approvals came through last month, expanding treatment options across multiple cancer types.

This approval makes durvalumab with FLOT chemotherapy the first perioperative immunotherapy for resectable gastric or gastroesophageal junction adenocarcinoma.

The FDA approved selumetinib for adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas based on the KOMET trial.

Only about 2% of cases of rhabdomyosarcoma primarily arise from the chest wall, and such cases require careful planning.

Global ovarian and uterine cancer cases due to high BMI have risen sharply over the past 30 years, especially in low- to middle-income sociodemoraphic regions.

Speakers at AMCP Nexus 2025 reviewed the oncology pipeline, highlighting expanded indications and new therapies advancing innovation, access, and value.

New reporting suggests obesity and diffuse large B-cell lymphoma (DLBCL) have shared genetic risk factors.

Treatment options for patients with small cell lung cancer (SCLC) who survive to a third line of therapy are insufficient, authors of a new study argue.

Many cancer survivors face ongoing physical and mental health challenges, which peer support and online resources can help address, says Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd.

Despite systemic challenges, oncology practices use value-based care, community partnerships, and clinical trials to improve patient access and outcomes, says Brian Mulherin, MD.

Vivek Subbiah, MD, says artificial intelligence (AI) should assist clinicians in precision oncology, not replace human decision-making.

Artificial intelligence, automation, and expanded pharmacist roles help reduce administrative burdens, improve workflow, and support providers in delivering cancer care, according to Scott Soefje, PharmD, MBA, BCOP.

Early research has identified several antigens that could help facilitate the use of chimeric antigen receptor T cells in small cell lung cancer.

Emotional well-being and social engagement significantly impact quality of life for patients with soft tissue sarcoma post-surgery.

Scott Soefje, PharmD, MBA, BCOP, discusses how remote patient monitoring and caregiver support enable safe outpatient delivery of bispecific antibodies and antibody-drug conjugates.

Stronger partnerships between primary care and oncology improve patient outcomes by ensuring coordinated care and addressing financial and systemic barriers, says Mark Fendrick, MD.

Reducing data silos and boosting transparency in oncology requires payer-provider trust and co-governance, according to Vishnukamal Golla, MD, MPH.

Although overall costs have not declined with the Oncology Care Model (OCM), supportive care costs have decreased through greater use of cost-effective therapies.

Vivek Subbiah, MD, considers artificial intelligence (AI) and comprehensive somatic and germline testing essential for guiding precision oncology and improving patient care.

Oncology pharmacists now work alongside providers to improve efficiency, patient education, and treatment outcomes, according to Scott Soefje, PharmD, MBA, BCOP.

Biomarkers like neutrophil-to-lymphocyte ratio could help predict treatment response to immune checkpoint inhibitors in certain patients with soft tissue sarcoma.

Second primary malignancies in patients with small cell lung cancer are often misdiagnosed as distant metastases.

Oncology care requires teamwork, support services, and careful planning to ensure effective, affordable, and patient-focused treatment, according to Brian Mulherin, MD.

Hope Krebill of the Masonic Cancer Alliance at the University of Kansas Medical Center outlines patient navigation models that improve outcomes and reduce missed appointments.

Davey Daniel, MD, shares strategies to prevent bias in artificial intelligence (AI) and outlining future opportunities for its adoption in precision oncology.

Atezolizumab or durvalumab, combined with platinum-doublet regimens, delivered superior responses and survival in patients often excluded from clinical trials.

Hope Krebill, MSW, BSN, RN, discusses the challenges rural hospitals face in delivering therapies like CAR T and bispecifics.

A phase 1b trial of tarlatamab plus PD-L1 inhibitors in extensive-stage small-cell lung cancer (ES-SCLC) showed a median overall survival of 25.3 months with manageable safety.

Multidisciplinary care influenced therapy choices but did not substantially shorten treatment delays for patients with sarcoma.